AstraZeneca's Tagrisso plus Orpathys aims to keep EGFR lung cancer patients on Tagrisso after resistance
- At ESMO 2026 AstraZeneca presented data for Tagrisso (osimertinib) plus Orpathys (savolitinib) in EGFR-mutated non-small cell lung cancer that has become resistant to Tagrisso.
- The SAFFRON Phase 3 enrolled MET-driven patients; August toplines reported better progression-free and overall survival than platinum chemotherapy.
- A US filing has been submitted, and the combination is already approved in China.
💡 Points
MET amplification is a leading way Tagrisso fails, so a combination that lets patients stay on the backbone gives AstraZeneca a lifecycle play on its biggest lung franchise. The market is narrow, since it depends on testing for MET-driven resistance, and rivals with EGFR-MET bispecifics are chasing the same patients.
#ESMO26: AstraZeneca's Tagrisso-Orpathys combo may extend Tagrisso's life in lung cancer ↗